PMEPA1 Activators comprise a chemical class designed to modulate the activity of the protein Prostate Transmembrane Protein, Androgen Induced 1 (PMEPA1). PMEPA1 is implicated in various cellular processes including signal transduction, protein degradation, and the regulation of transcription factors, such as the androgen receptor. The protein is known to be involved in the ubiquitination pathway, targeting specific proteins for degradation by the proteasome.
The activation of PMEPA1 by these chemicals can be achieved through direct or indirect means. Direct activators may bind to PMEPA1 and enhance its stability or its interaction with other proteins, such as NEDD4, a ubiquitin ligase that PMEPA1 is known to interact with, thereby potentially increasing the ubiquitination and subsequent degradation of target proteins. These activators could also influence the post-translational modifications of PMEPA1, modifying its activity or the spectrum of its protein interactions. Indirect PMEPA1 activators may affect the signaling pathways that control the expression of the PMEPA1 gene, leading to increased production of the protein. They could also modulate the activity of proteins that interact with PMEPA1, thereby altering its function. For example, they could inhibit the degradation of PMEPA1, resulting in enhanced levels of the active protein, or they could increase the transcriptional activity of factors that upregulate PMEPA1 expression. The exploration of PMEPA1 Activators is important in research as it contributes to the understanding of protein regulation via the ubiquitin-proteasome system. PMEPA1's role in this system makes it a key player in the control of protein turnover, a fundamental aspect of cellular homeostasis. By studying PMEPA1 Activators, scientists can gain insights into the mechanisms that control protein degradation and the complex regulatory networks that ensure cellular proteins are precisely expressed and maintained at the correct levels.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Adenylyl cyclase activator that increases cAMP, leading to PKA activation which can phosphorylate proteins in signaling pathways where PMEPA1 is a component, therefore enhancing PMEPA1 activity indirectly. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MEK inhibitor that indirectly enhances PMEPA1 activity by altering the ERK/MAPK signaling pathway in which PMEPA1 is a regulatory factor. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor that modifies downstream Akt signaling, potentially enhancing PMEPA1 activity by affecting its role in the pathway. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
Raf kinase inhibitor that can influence PMEPA1 activity through modulation of the MAPK/ERK pathway, in which PMEPA1 has a functional role. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor that could enhance PMEPA1 activity by affecting the JNK signaling pathway that intersects with PMEPA1's regulatory functions. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
AMPK activator that can enhance PMEPA1 activity by modulating cellular energy pathways that intersect with PMEPA1's role in the cell. | ||||||
Zoledronic acid, anhydrous | 118072-93-8 | sc-364663 sc-364663A | 25 mg 100 mg | $92.00 $256.00 | 5 | |
Bisphosphonate that inhibits farnesyl pyrophosphate synthase, potentially enhancing PMEPA1 activity due to PMEPA1's involvement in bone metabolism and response to bisphosphonates. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Histone deacetylase inhibitor that can enhance PMEPA1 activity indirectly by altering chromatin structure and affecting transcriptional programs involving PMEPA1. | ||||||